Menlo Park, California, USA, August 8, 2026
GRAIL, Inc. has announced a major regulatory milestone as the U.S. Food and Drug Administration (FDA) schedules a meeting of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee on September 23, 2026, to review the Premarket Approval (PMA) application for the Galleri® multi-cancer early detection (MCED) blood test. The advisory committee review represents a critical step in the FDA’s evaluation of what could become the first FDA-approved multi-cancer early detection blood test capable of detecting cancer signals before symptoms appear. Designed to identify cancer-specific methylation patterns across multiple tumor types, the Galleri test aims to complement existing guideline-recommended cancer screening rather than replace current screening programs. The review follows years of extensive clinical research involving tens of thousands of participants and highlights the growing role of artificial intelligence, next-generation sequencing, and precision diagnostics in transforming early cancer detection and improving patient outcomes through earlier diagnosis.
Galleri Test Expands Multi-Cancer Early Detection
The Galleri® test is designed to detect methylation signatures associated with multiple cancer types using a simple blood sample before clinical symptoms develop. Unlike conventional screening methods that focus on individual cancers such as breast, colorectal, or cervical cancer, Galleri is intended to identify signals from multiple cancers simultaneously, including several aggressive cancers that currently have no recommended population screening tests. Following detection of a cancer signal, the test is also designed to accurately predict the tissue of cancer origin, providing physicians with valuable information to guide diagnostic evaluation. Importantly, GRAIL emphasizes that the Galleri test is intended to be used alongside standard screening programs, supporting comprehensive cancer detection rather than replacing established screening recommendations. By combining targeted methylation analysis, artificial intelligence algorithms, and advanced genomic technologies, Galleri represents a significant advancement in the evolving field of liquid biopsy diagnostics and precision oncology.
Extensive Clinical Evidence Supports FDA Review
The FDA’s advisory committee review will evaluate the extensive clinical evidence submitted as part of GRAIL’s Premarket Approval application, which was filed in January 2026. The submission includes safety and performance data from approximately 25,490 participants enrolled in the PATHFINDER 2 study, representing one of the largest U.S.-based investigations of multi-cancer early detection. Additional supporting evidence comes from more than 70,000 participants enrolled in the NHS-Galleri Trial, the largest randomized controlled study of an MCED blood test conducted in an intended-use population. Together, these large-scale clinical programs demonstrated encouraging performance, including high cancer signal origin prediction accuracy, a low false-positive rate, and the ability to detect cancers that often remain undiagnosed until advanced stages. The FDA also designated Galleri as a Breakthrough Device, recognizing its potential to address a significant unmet need in cancer screening and accelerate regulatory review of innovative diagnostic technologies.
Advertisement
Precision Diagnostics May Transform Cancer Screening
The upcoming advisory committee meeting represents an important milestone not only for GRAIL but also for the broader field of precision medicine and early cancer detection. Many cancer-related deaths occur because malignancies are diagnosed only after symptoms emerge, limiting treatment options and reducing survival rates. By leveraging next-generation sequencing, machine learning, and proprietary methylation analysis technology, Galleri seeks to identify cancers earlier when treatment may be more effective and potentially curative. If ultimately approved by the FDA, the Galleri test could become the first commercially approved multi-cancer early detection blood test, expanding access to innovative screening approaches capable of complementing current public health programs. The advisory committee’s scientific review will play a key role in determining the future of blood-based cancer screening, potentially establishing a new standard for detecting multiple cancers through minimally invasive precision diagnostic technology.
Source: GRAIL press release
